JP6482524B2 - 抗ｃｄ５２抗体 - Google Patents

抗ｃｄ５２抗体 Download PDF

Info

Publication number
JP6482524B2
JP6482524B2 JP2016502067A JP2016502067A JP6482524B2 JP 6482524 B2 JP6482524 B2 JP 6482524B2 JP 2016502067 A JP2016502067 A JP 2016502067A JP 2016502067 A JP2016502067 A JP 2016502067A JP 6482524 B2 JP6482524 B2 JP 6482524B2
Authority
JP
Japan
Prior art keywords
antibody
seq
antibodies
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2016502067A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016518333A5 (enExample
JP2016518333A (ja
Inventor
ホアウエイ・チウ
ロニー・ロン・ウエイ
クラーク・クン・パン
レベッカ・センダック
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50391542&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6482524(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of JP2016518333A publication Critical patent/JP2016518333A/ja
Publication of JP2016518333A5 publication Critical patent/JP2016518333A5/ja
Application granted granted Critical
Publication of JP6482524B2 publication Critical patent/JP6482524B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2016502067A 2013-03-15 2014-03-13 抗ｃｄ５２抗体 Expired - Fee Related JP6482524B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361794576P 2013-03-15 2013-03-15
US61/794,576 2013-03-15
PCT/US2014/026159 WO2014151644A2 (en) 2013-03-15 2014-03-13 Anti-cd52 antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018229547A Division JP2019069960A (ja) 2013-03-15 2018-12-07 抗ｃｄ５２抗体

Publications (3)

Publication Number Publication Date
JP2016518333A JP2016518333A (ja) 2016-06-23
JP2016518333A5 JP2016518333A5 (enExample) 2017-04-13
JP6482524B2 true JP6482524B2 (ja) 2019-03-13

Family

ID=50391542

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016502067A Expired - Fee Related JP6482524B2 (ja) 2013-03-15 2014-03-13 抗ｃｄ５２抗体
JP2018229547A Pending JP2019069960A (ja) 2013-03-15 2018-12-07 抗ｃｄ５２抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018229547A Pending JP2019069960A (ja) 2013-03-15 2018-12-07 抗ｃｄ５２抗体

Country Status (35)

Country Link
US (2) US9708407B2 (enExample)
EP (1) EP2970467B1 (enExample)
JP (2) JP6482524B2 (enExample)
KR (1) KR20150131286A (enExample)
CN (1) CN105209495B (enExample)
AR (1) AR095199A1 (enExample)
AU (1) AU2014233685B2 (enExample)
BR (1) BR112015022464A2 (enExample)
CA (1) CA2906539A1 (enExample)
CL (1) CL2015002705A1 (enExample)
CR (1) CR20150547A (enExample)
CY (1) CY1121795T1 (enExample)
DK (1) DK2970467T3 (enExample)
DO (1) DOP2015000211A (enExample)
EA (1) EA031730B1 (enExample)
ES (1) ES2710976T3 (enExample)
GT (1) GT201500267A (enExample)
HR (1) HRP20190085T1 (enExample)
HU (1) HUE041796T2 (enExample)
IL (1) IL241410A0 (enExample)
LT (1) LT2970467T (enExample)
MA (1) MA38485A1 (enExample)
MX (1) MX2015012991A (enExample)
NZ (1) NZ631473A (enExample)
PE (1) PE20151757A1 (enExample)
PH (1) PH12015501932A1 (enExample)
PL (1) PL2970467T3 (enExample)
PT (1) PT2970467T (enExample)
SG (1) SG11201506932SA (enExample)
SI (1) SI2970467T1 (enExample)
TN (1) TN2015000415A1 (enExample)
TR (1) TR201900638T4 (enExample)
TW (1) TWI644923B (enExample)
UY (1) UY35440A (enExample)
WO (1) WO2014151644A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2429582A4 (en) 2009-05-13 2013-01-23 Genzyme Corp IMMUNOGLOBULINS ANTI-CD52 HUMAN
KR101800467B1 (ko) 2009-05-13 2017-11-22 젠자임 코포레이션 루푸스 치료 방법 및 조성물
EP4037233B1 (en) * 2014-01-28 2023-10-04 Huawei Technologies Co., Ltd. Data transmission indication method, access point and terminal
JP7219721B2 (ja) * 2017-04-21 2023-02-08 ジェンザイム・コーポレーション 抗ｃｄ５２抗体を用いて多発性硬化症を処置するための経路およびスケジュール
BR112020015915A8 (pt) * 2018-02-13 2023-01-31 Merck Sharp & Dohme Usos de um anticorpo anti-pd-1 e um anticorpo anti-ctla4 ou fragmentos de ligação ao antígeno dos mesmos, bem como kit para tratamento de um paciente com câncer
CU20210096A7 (es) 2019-05-21 2022-06-06 Novartis Ag Moléculas de unión a cd19
EP4003375A4 (en) * 2019-07-31 2023-09-06 Forty Seven, Inc. DEPLETION DIETS FOR MODIFIED T CELL OR NK CELL THERAPY
EP4574840A1 (en) * 2022-08-15 2025-06-25 The University of Tokyo Method for producing immunoglobulin or multimer immunoglobulin using filamentous fungus
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6054561A (en) 1984-02-08 2000-04-25 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4970198A (en) 1985-10-17 1990-11-13 American Cyanamid Company Antitumor antibiotics (LL-E33288 complex)
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
WO1987006265A1 (fr) 1986-04-17 1987-10-22 Kyowa Hakko Kogyo Co., Ltd. Nouveaux composes dc-88a et dc-89a1, et procede pour leur preparation
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
JP3095168B2 (ja) 1988-02-05 2000-10-03 エル． モリソン，シェリー ドメイン‐変性不変部を有する抗体
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JP2598116B2 (ja) 1988-12-28 1997-04-09 協和醗酵工業株式会社 新規物質ｄｃ１１３
US5187186A (en) 1989-07-03 1993-02-16 Kyowa Hakko Kogyo Co., Ltd. Pyrroloindole derivatives
JP2510335B2 (ja) 1989-07-03 1996-06-26 協和醗酵工業株式会社 Ｄｃ―８８ａ誘導体
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2089661C (en) 1990-08-29 2007-04-03 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
GB9022547D0 (en) 1990-10-17 1990-11-28 Wellcome Found Purified immunoglobulin
GB9022543D0 (en) 1990-10-17 1990-11-28 Wellcome Found Antibody production
GB9108056D0 (en) 1991-04-16 1991-06-05 Hale Geoffrey Synthetic antigen
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
US5264586A (en) 1991-07-17 1993-11-23 The Scripps Research Institute Analogs of calicheamicin gamma1I, method of making and using the same
US5269388A (en) 1991-11-12 1993-12-14 Stress-Tek, Inc. Weighing bed
GB9125768D0 (en) 1991-12-04 1992-02-05 Hale Geoffrey Therapeutic method
WO1994026087A2 (en) 1993-05-14 1994-11-24 Connor Kim C O Recombinant protein production and insect cell culture and process
EP0714409A1 (en) 1993-06-16 1996-06-05 Celltech Therapeutics Limited Antibodies
US7119248B1 (en) 1994-04-12 2006-10-10 Miltenyi Biotec Gmbh Antibodies against epitopes with homology to self antigens, methods of preparation and applications thereof
PT705833E (pt) 1994-04-22 2004-11-30 Kyowa Hakko Kogyo Kk Derivado de dc-89
US5550246A (en) 1994-09-07 1996-08-27 The Scripps Research Institute Calicheamicin mimics
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
US6172213B1 (en) 1997-07-02 2001-01-09 Genentech, Inc. Anti-IgE antibodies and method of improving polypeptides
ES2278463T3 (es) 1998-12-08 2007-08-01 Biovation Limited Metodo para reducir la inmunogenicidad de proteinas.
PT1242401E (pt) 1999-11-24 2007-03-30 Immunogen Inc Agentes citotóxicos compreendendo taxanos e o seu uso terapêutico
JP5198704B2 (ja) 2000-03-03 2013-05-15 メディミューン リミティド エオタキシンに対するヒト抗体及びそれらの使用
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
US7465790B2 (en) 2000-10-09 2008-12-16 Isis Innovation, Inc. Therapeutic antibodies
US20020132983A1 (en) 2000-11-30 2002-09-19 Junghans Richard P. Antibodies as chimeric effector cell receptors against tumor antigens
US7771951B2 (en) 2001-12-03 2010-08-10 Amgen Fremont Inc. Antibody categorization based on binding characteristics
AU2002362197A1 (en) 2001-12-28 2003-07-24 Chugai Seiyaku Kabushiki Kaisha Method of stabilizing protein
AU2003217912A1 (en) 2002-03-01 2003-09-16 Xencor Antibody optimization
US20050191632A1 (en) 2002-11-01 2005-09-01 John Byrd Cytogenetic abnormalities that are predictive of response to therapy for chronic lymphocytic leukemia
CN1225480C (zh) 2002-12-18 2005-11-02 马菁 抗cd52单克隆抗体、其编码序列及应用
US7534427B2 (en) 2002-12-31 2009-05-19 Immunomedics, Inc. Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
US20060228351A1 (en) 2003-03-31 2006-10-12 Junichi Masuyama Method of inducing differentiation and proliferating regulatory t cell by anti-cd52 antibody and medicinal composition therefor
CA2526120A1 (en) 2003-06-03 2005-02-24 Cell Genesys, Inc. Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site
WO2005042581A2 (en) 2003-11-01 2005-05-12 Biovation Ltd. Modified anti-cd52 antibody
US20060204496A1 (en) 2003-11-28 2006-09-14 Tetsuo Kojima Agonist antibody against heteroreceptor
ITRM20030601A1 (it) * 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
US7655229B2 (en) 2004-09-02 2010-02-02 Chan Andrew C Anti-FC-gamma RIIB receptor antibody and uses therefor
AP2007004250A0 (en) 2005-05-24 2007-12-31 Avestha Gengraine Tech Pvt Ltd Recombinant method for the production of a monoclonal antibody to cd52 for the treatment of chronic lymphocytic leukemia
KR101679468B1 (ko) * 2005-05-27 2016-11-24 바이오젠 엠에이 인코포레이티드 Ｔｗｅａｋ 결합 항체
PL1966244T3 (pl) 2005-12-30 2012-08-31 Merck Patent Gmbh Przeciwciała anty-il-6 zapobiegające wiązaniu il-6 skompleksowanego z il-6ralpha do gp130
CA2649440A1 (en) 2006-04-12 2007-10-25 Genzyme Corporation Methods of treating autoimmune diseases
SI2066352T1 (sl) 2006-09-13 2016-05-31 Alcafleu Management Gmbh & Co. Kg Zdravljenje multiple skleroze (MS) s Campath-1 H
US9498528B2 (en) 2006-09-13 2016-11-22 Genzyme Corporation Treatment of multiple sclerosis (MS)
NZ579297A (en) * 2007-02-28 2012-03-30 Schering Corp Combination therapy comprising an il-23 antagonist and a cytokine antagonist for treatment of immune disorders
EP2160408A1 (en) 2007-06-22 2010-03-10 Bayer Schering Pharma Aktiengesellschaft Use of antibodies against the cd52 antigen for the treatment of neurological disorders, particularly transmissible spongiform encephalopathy and alzheimer's disease
EP2429582A4 (en) * 2009-05-13 2013-01-23 Genzyme Corp IMMUNOGLOBULINS ANTI-CD52 HUMAN
KR101800467B1 (ko) 2009-05-13 2017-11-22 젠자임 코포레이션 루푸스 치료 방법 및 조성물
US20120058082A1 (en) 2009-05-13 2012-03-08 Genzyme Corporation Methods and compositions for treatment
AU2010271582B2 (en) * 2009-07-15 2016-07-28 Aimm Therapeutics B.V. Gram-positive bacteria specific binding compounds
JP6266343B2 (ja) * 2010-07-16 2018-01-24 アディマブ， エルエルシー 抗体ライブラリー

Also Published As

Publication number Publication date
CN105209495A (zh) 2015-12-30
US20160024219A1 (en) 2016-01-28
AU2014233685B2 (en) 2019-02-28
UY35440A (es) 2014-10-31
WO2014151644A2 (en) 2014-09-25
HRP20190085T1 (hr) 2019-03-08
SI2970467T1 (sl) 2019-03-29
MX2015012991A (es) 2015-12-15
LT2970467T (lt) 2019-02-11
EA031730B1 (ru) 2019-02-28
ES2710976T3 (es) 2019-04-29
TR201900638T4 (tr) 2019-03-21
KR20150131286A (ko) 2015-11-24
DOP2015000211A (es) 2015-11-30
GT201500267A (es) 2017-12-15
JP2019069960A (ja) 2019-05-09
MA38485A1 (fr) 2017-06-30
HK1219963A1 (en) 2017-04-21
TWI644923B (zh) 2018-12-21
HUE041796T2 (hu) 2019-05-28
IL241410A0 (en) 2015-11-30
US20170349665A1 (en) 2017-12-07
US9708407B2 (en) 2017-07-18
EP2970467A2 (en) 2016-01-20
EA201591796A1 (ru) 2016-01-29
WO2014151644A3 (en) 2015-01-15
TW201522373A (zh) 2015-06-16
CA2906539A1 (en) 2014-09-25
NZ631473A (en) 2017-09-29
EP2970467B1 (en) 2018-10-17
PE20151757A1 (es) 2015-12-03
CR20150547A (es) 2016-01-08
JP2016518333A (ja) 2016-06-23
PL2970467T4 (pl) 2019-07-31
TN2015000415A1 (en) 2017-01-03
PH12015501932A1 (en) 2016-01-04
DK2970467T3 (en) 2019-02-11
AU2014233685A1 (en) 2015-10-01
SG11201506932SA (en) 2015-09-29
AR095199A1 (es) 2015-09-30
PL2970467T3 (pl) 2019-07-31
PT2970467T (pt) 2019-01-28
CL2015002705A1 (es) 2016-04-22
CN105209495B (zh) 2020-06-26
BR112015022464A2 (pt) 2017-10-24
CY1121795T1 (el) 2020-07-31

Similar Documents

Publication Publication Date Title
JP6482524B2 (ja) 抗ｃｄ５２抗体
US20220010024A1 (en) Anti-Human CD52 Immunoglobulins
EP3128997B1 (en) Binding molecules specific for il-21 and uses thereof
EP2725037A1 (en) Monoclonal antibodies binding canine CD20
CN112794911B (zh) 人源化抗叶酸受体1抗体及其应用
AU2017202364B2 (en) Anti-human CD52 immunoglobulins
HK1219963B (en) Anti-cd52 antibodies
TW202409080A (zh) 用於治療卵巢癌之組合療法
OA17634A (en) Anti-CD52 antibodies.
HK40031443A (en) Binding molecules specific for il-21 and uses thereof
NZ762893B2 (en) Binding molecules specific for il-21 and uses thereof
HK40031934A (en) Anti-human cd52 immunoglobulins
NZ725735B2 (en) Binding molecules specific for il-21 and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170310

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170310

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180403

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180703

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180807

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181207

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20181218

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190115

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190212

R150 Certificate of patent or registration of utility model

Ref document number: 6482524

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees